Alzheimer's breakthrough? Hay fever drug rejuvenates the brain and REVERSES ageing process
A COMMONLY-PRESCRIBED asthma drug could hold the key to slowing or even REVERSING the deterioration of cells in the brain, marking a significant step forward in the fight to beat dementia.
Pioneering research by an Austrian team of scientists found montelukast, which is sold under the brand name Singulair and is used to treat asthma and allergic reacts including hay fever, actually reversed the ageing process in a study on rat brains.
The results are significant enough to warrant a clinical trial on people suffering from Parkinson's disease.
In tests on memory and cognition, the older rats which had been given an oral dose equivalent to that taken by people with asthma performed just as well as the younger rats.
Neuroscientist Ludwig Aigner, of the Paracelsus Medical University in Salzburg, and his colleagues targeted a set of receptors in the brain that trigger inflammation, which is linked to Alzheimer's disease and Huntingdon's disease.